New drug for early-stage bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug, RAG-01, given alone or with chemotherapy, for people with a type of bladder cancer that hasn't spread into the muscle. The goal is to see if it can help treat the cancer and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of non-muscle-invasive bladder cancer (NMIBC) that is either intermediate or high risk.
- You cannot have any remaining tumors that can be removed with surgery at the start of the study.
- You must be willing to provide tissue samples for research.
- You must be in generally good health, with a performance status of 0 or 1, meaning you can care for yourself and are up and about.
- You must agree to use effective birth control during the study and for 3 months after treatment if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Hear when a new Non-muscle Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.